Introduction
The common genetic disorder neurofibromatosis type1 (NF1, MIM: #162200) is a familial cancer syndrome that is characterized by a high incidence of neurofibromas, bone deformations, pigmentation anomalies, learning disabilities and a number of additional features (Riccardi, 1992; Upadhyaya and Cooper, 1998 ) that contribute to a rather complex disease phenotype. Alterations in the tumor suppressor gene NF1
(HGNC:7765, MIM: *613113, RefSeq: NM_000267.3), encoding the cytoplasmic protein neurofibromin (320 kDa, 2818aa, RefSeq: NP_000258.1, UniProtKB P21359-2) (Le and Parada, 2007; McClatchey and Cichowski, 2001; Viskochil, et al., 1993; Zhu and Parada, 2001) , are responsible for the pathogenesis of NF1. Neurofibromin is a Ras specific GTPase activating protein (RasGAP) with a central segment termed GAP related domain (GRD, Figure 1a ) that has been extensively characterized in numerous laboratories including ours (Cichowski and Jacks, 2001; Zhu and Parada, 2001) . Of the mutational spectrum of NF1 the majority of alterations found in NF1-patients result in premature stop codons most likely leading to elimination of the transcript by the RNA surveillance machinery or to truncated peptides incompatible with a functional protein. Approximately 10% of alterations are compatible with a missense mutated protein, although the production of such protein has not been verified in many cases (Fahsold, et al., 2000; Shen, et al., 1996) .
Largely, the missense mutations are distributed uniformly over neurofibromin, with clusters in the GRD region and the so-called cysteine-serine-rich-domain (CSRD, Figure 1a ) (Izawa, et al., 1996) , suggesting this domain to be of functional importance as well (Fahsold, et al., 2000) . While numerous binding partners of neurofibromin have been reported (Patrakitkomjorn, et al., 2008; Phan, et al., 2010; Welti, et al., 2008) , the physiological significance of the underlying protein-protein Welti, et al., 2007) . A number of missense mutations of the Sec14-PH module have been identified in NF1-patients as well as single and double amino acid deletions (Table   1 ). In addition a tandem duplication (TD, see Table 1 ) of 14 amino acids was observed with the affected patients displaying features linked to Watson-and Noonan syndrome (Tassabehji, et al., 1993) . Mapping these alterations onto the Sec14-PH structure suggests moderate structural changes in most cases. In contrast, deletion or insertion mutants as found in exposed regions are unlikely to leave the structure unchanged. In order to define/model the local effect of NF1 associated non-truncating mutations and to investigate whether they would interfere with lipid binding or protein stability we have overexpressed and purified the respective Sec14-PH-mutants from an E. coli expression system. Purified proteins were subject to biochemical analysis including CD spectroscopy and lipid binding assays monitored by mass spectrometry. Selected mutants of potential structural impact were analyzed by X-ray crystallography, for two of which we also demonstrate normal mRNA and protein levels in patient-derived cultured cells. 
Materials and Methods
Nucleotide and codon numbering is based on the cDNA reference sequence. Codon 1 is the initiation codon ATG with the Nucleotides +1 to +3, according to journal guidelines (www.hgvs.org/mutnome).
Cloning, Expression and purification of HsNF1 Sec14-PH and variants: The Sec14-PH region (residues 1545-1816) of human neurofibromin (Bonneau, et al., 2004; D'Angelo, et al., 2006; Welti, et al., 2007) was amplified from cDNA by PCR and cloned (Sambrook and Russell, 2001 ) into the pETM11 expression vector (EMBL, protein expression and purification core facility). All deletion and point mutations were made by using the Quickchange site-directed mutagenesis kit (Stratagene) following manufacturer's instructions. The tandem duplication mutant TD was generated via two PCR reactions (see primers, Supp. Imidazol, pH8.1) with 1 µg/ml Lysozym (Sigma-Aldrich) and DNaseI (Roche), followed by sonication (5x2 min, duty cycle 50%, power 5; Branson W-250, Heinemann). After an ultracentrifugation step (40.000 rpm, 1 h , 277K), the cell lysate was continuously applied to a pre-equilibrated 1 ml HisTrap column (GE healthcare) in a circulatory way for 2 h and washed with 10 ml buffer LyB. Following 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Liposome preparation, lipid exchange assay and mass spectrometry: The preparation of liposomes, lipid exchange assays and extraction of lipids from protein samples for MS analysis was done as previously described (Welti, et al., 2007) .
Liposomes consisted of 6.88% Sphingomyelin (SM, brain); 14.27% 1,2-dioleoyl-snglycero-3-phosphocholine (DOPC); 54.28% 1-palmitoyl(D31)-2-oleoyl-sn-glycero-3-phosphoethanolamine (D31PE); 22.17% L-α-phosphatidylinositol (PI, bovine liver) and 2.45% 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS, all lipids from Avanti Polar lipids inc.) mimicking thereby the lipid composition of the inner leaflet of plasma membranes as observed in mammalian cells (Calderon and DeVries, 1997) .
For lipid mass spectrometry, samples were extracted in the presence of internal standards (Brugger, et al., 2006) . After solvent evaporation, the samples were resuspended in 10 mM ammonium acetate in methanol. Quantification of lipids was performed in positive ion mode on a triple-stage quadrupole tandem mass spectrometer (QII, Micromass) equipped with a nano-ESI source (Z spray). Argon was used as collision gas at a nominal pressure of 2.5 x 10 -3 millibar. The cone voltage was set to 30 V (50 V for PC analysis). The quadrupoles Q1 and Q3 were operated at unit resolution. Detection of PC was achieved by precursor ion scanning for the fragment ion m/z 184 at a collision energy (CE) of 32 eV. PE, PI, PS, and PG Datasets were collected under cryogenic conditions (100 K) at the European Synchrotron Radiation Facility Grenoble (ESRF) and processed with XDS (Kabsch, 1993) . For structure determination, the wild-type HsNF1 Sec14-PH structure (Welti, 2007 ; PDB code 2E2X) was used either directly as starting model for refinement or as search model in molecular replacement calculations using CNS (Brunger, et al., 1998) in case of TD1699-1713. Refinement was carried out with CNS, CCP4/Refmac (CCP4, 1994; Murshudov, et al., 1997) or Phenix (Adams, et al., 2002) , alternating with manual rebuilding using COOT (Emsley and Cowtan, 2004) .
TLS groups were selected based on analysis with TLSMD (Painter and Merritt, 2006; Painter, 2006) . A summary of the crystallographic analysis is presented in Table 2 .
Quantification of neurofibromin from patient-derived cultured cells:
The investigated NF1-patients correspond to the NIH criteria and gave informed consent prior to the blood isolation. The 28 and 35-year old sporadic NF1 patients exhibited typical symptoms of NF1: more than 100 cutaneous and subcutaneous Neurofibromin amounts were assessed by immunoprecipitation using equal amounts of total protein (250 or 500 µg) from cultured peripheral blood cells of NF1-patients and controls. Detection of the protein was done by Western-blot analysis (Griesser, et al., 1997) using the sc-67 and sc-68 antibodies from Santa Cruz Biotechnology.
As described previously (Kaufmann, et al., 1999a) , the expression levels of p120-GAP and ß-tubulin were analyzed as control. Resulting protein bands were quantitatively evaluated by video-densitometry.
Results and Discussion
NF1 associated missense non-truncating mutations of the Sec14-PH module were engineered by site directed mutagenesis of the human Sec14-PH coding sequence, expressed in E. coli and purified as described in the Methods section. Apart from a few exceptions (see below), the majority of the mutants was soluble and folded as confirmed by size exclusion chromatography and CD spectroscopy, allowing the assessment of lipid binding and exchange activity. Expression of mutants was analyzed in human cultured peripheral blood cells if source material was available.
Three prominent mutations based on their location in the structure and/or due to availability of clinical data were analyzed by X-ray crystallography.
Most NF1-associated Sec14-PH non-truncating mutations retain exchange of glycerophospholipids
The engineered non-truncating mutations were subject to lipid exchange assays Figure S1 ). Interestingly most mutations located close to the Sec14 lipid binding pocket were poorly soluble in our production scheme, suggesting that interfering with the structure of the lipid binding pocket may disrupt essential structural elements.
NF1-p.K1750del and p.I1584V mutant proteins are fully expressed in patients
We investigated the stability of mutated neurofibromin in cells of NF1-patients with the suggested missense non-truncating mutations NF1-p.K1750del (exon 29, c.5248_5250delAAA) and NF1-p.I1584V (exon 27b, c.4750A>G) (Fahsold, et al., 2000) . Using immunoprecipitation and Western Blot experiments, we showed that the total amount of expressed neurofibromin is not reduced in two NF1-patients compared to healthy donors ( Figure 2 ). These data were confirmed by real-time RT-PCR investigations of NF1 mRNA levels in cells of these patients, indicating unchanged expression levels (data not shown). Since the amounts of mRNA and protein are not reduced or increased compared to the wild-type situation, we conclude that the two alterations represent functional non-truncating mutations. Their pathogenic effect might be caused rather by modification or disruption of intra-or intermolecular protein-protein / ligand interaction surfaces than by mRNA degradation, decrease of protein stability or insolubility. Figure S2 ). To verify the integrity of the purified mutants, we subsequently assessed their oligomeric state by analytical gelfiltration (Supp. Figure S3 ), the overall fold with CD spectroscopy (Supp. Figure S4 ) and their stability by thermal denaturation experiments (Supp. Figure S5 ). The analyzed properties of mutants were not impaired, with the exception of the thermal stability of TD and p.K1750del, which was significantly lowered ( Mutant proteins were purified, crystallized and their structures solved as described in the methods section. The crystallographic analysis is summarized in Table 2 . The overall structure is largely similar to that of the wild type Sec14-PH portions (D'Angelo, et al., 2006; Welti, et al., 2007 , Figure 1b ) with local alterations due to the respective ligand yet to be established.
Recombinant Sec14-PH(p.K1750del) and (p.I1584V) modules are folded

TD:
The reported tandem duplication has been found in a patient displaying a heterogenous phenotype compatible with Watson-and Noonan-Syndrome (Tassabehji, et al., 1993) (MIM #193520 and #601321). Essentially, the linker peptide connecting the Sec14-and PH-like portions of neurofibromin is duplicated.
The crystal structure shows the resulting segment (residues 1699' to 1712', Figure   1c ; ' denotes duplicated residues) largely disordered with flanking regions slightly displaced and parts of the helical portion unwound. Despite the significant steric challenges imposed by the inserted peptide segment, the relative orientation of the two domains is rather similar to that observed in the wild-type situation. Given the presumably exposed arrangement of the lid-protrusion in the full length neurofibromin protein (A. Parret, unpublished observation), it is in fact likely that the linker region is exposed on the protein surface as well. Furthermore, the crystal structure points to a high flexibility of the duplicated linker, which is supported by thermal denaturation measurements showing unfolding at a significantly lower temperature compared with the wild type protein (Supp. Figure S5 Figure S6 ) or the glycerophospholipid exchange activity of the Sec14 cage (Supp. Figure S1 ), we suggest that a so far unknown ligand binding activity involving the lid-lock region is impaired, consistent with the structural effects of p.K1750del and its reduced capability to bind PtdInsP.
Taking into account that the lid-lock region appears to be accessible in the full length protein (A. Parret, unpublished observation), we would expect an intermolecular contact surface in this area. As potential ligands, certain phosphoproteins or similar species with strong local negative charges could be imagined besides PtdInsPs. (2818aa) showing the Sec14, pleckstrin homology (PH) like, cystein and serine rich-(CSRD) and GAP related domain (GRD). Domains are drawn to scale. b) Structure of the wild-type Sec14-PH domains of neurofibromin with positions where selected patient-derived alterations have been observed highlighted in yellow. c) Superposition of TD (green) with the wild-type protein (red/yellow/violet). The overall fold and orientation of the Sec14 and PH domains is conserved. In the mutant structure, the linker region is not visible (green dashed line), indicating a high flexibility of the region. A ' denotes duplicated residues. d) p.K1750del induces a structural rearrangement in the "lock" region. The wild-type structure is shown in red, p.K1750del in orange. R1748 is flipped to the former position of T1749, which is now oriented like the deleted K1750. Therewith, K1750 and R1748 are no longer available for ligand binding. e) Superposition of the p.I1584V (green) and wild-type (violet) structure. Mutant and wild-type structures show virtually no differences apart from the p.I1584V amino acid substitution, which is well defined in the electron density map (orange).
Figure 2:. Determination of neurofibromin content in the NF1 patients. Normal neurofibromin levels were found in NF1-p.K1750del and NF1-p.I1584V as compared with healthy donors (K1, K2 and K3). Reduced neurofibromin levels were detected in NF1 patients with truncating mutations (NF71, NF10 and NF106 (Kaufmann, et al., 1999b) ). Neurofibromin content was measured in peripheral blood cells by immunoprecipitation and Western blotting as described (Griesser, et al., 1997; Klose, et al., 1998) . Lipid profiles of wild-type NF1 Sec14-PH and selected representative mutants. Following liposomal exchange assays, proteins were subjected to quantitative lipid analysis by nano-mass spectrometry. Data are the mean ± margin of deviation of three different experiments; for input values n =1. "Input" corresponds to the lipid content of the wild-type NF1 Sec14-PH protein prior to lipid exchange.
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Human Mutation
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